Pain Management Drugs Market, by Drug Class (Opioids, NSAIDs, Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region - Global Forecast to 2026

  • Published On : May 2018 |
  • Pages : 205 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Pain Management Drugs Market – Insights

Pain management medications are specific drug classes, which have pharmacological actions on pain receptors and work against the pain symptoms. These medications include opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, muscle relaxants, and others. These medications can be used for pain management of conditions, as indicated on label and some medications have off-label uses. For instance, anticonvulsants and antidepressants were originally used for the management of epilepsy and depression respectively. However, these medications have shown activity against pain indications and are prescribed for pain management as off-label indication. Moreover, opioids are majorly prescribed for the management of acute as well as chronic pain. This has also resulted in self-medication by patients, resulting in misuse or overdose of opioid containing drug products. Moreover, majority of the drugs have lost patent protection over the years and generic versions of the same are widely available in the market. Commercially available pain management drugs include Fentanyl, Hydromorphone, Oxycodone, Aspirin, Diazepam, and others.

Lack of alternative treatment therapies are projected to drive growth of pain management drugs market over the forecast period

In 2015, Depomed, Inc. acquired the U.S. rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended release tablets, and NUCYNTA (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. Tapentadol is available in tablet, solution, and extended release forms. Furthermore, the tablet and solution forms of NUCYNTA has three patents, out of which one expired in June 2017 and other two will expire in June 2025 and August 2029, respectively. Moreover, patent expiry of pain management drugs such as Oxycontin, Opana, Celebrex (2013 - 2014), and others are providing opportunity to market players for introducing new products in the pain management drugs market.

Moreover, introduction of novel drug delivery systems such as prefilled syringes and injectable dosage are offered by manufacturers such as Pfizer, Inc., which is expected to boost the market growth over the forecast period. Manufacturers offer wide range of products, which include generic as well as branded products in capsules and tablet forms. Also, some of the drugs are cost-effective alternative as compared to the pain therapies such as invasive approach and physiotherapy. These factors are further expected to boost the market growth over the forecast period.

The global pain management drugs market was valued at US$ 63,212.3 Mn in 2017 and is expected to witness a robust CAGR of 3.9% over the forecast period (2018 – 2026).

Figure 1. Global Pain Management Drugs Market Value (US$ Mn), by Region, 2018 and 2026

pain management drugs market

Source: Coherent Market Insights Analysis (2017)

High prevalence of chronic pain diseases is expected to foster the growth of pain management drugs market over the forecast period

According to the American Academy of Pain Medicine, in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society, around 50 million people in the U.S. suffered from chronic pain. Moreover, rising prevalence of pain and increasing prevalence of diseases such as cancer and others are driving growth of the pain management drugs market. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease.

However, side effects associated with the pain management drugs and addiction issues with the opioid medications are expected to hinder growth of the pain management drugs market over the forecast period.

Some major players operating in the pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.

Pain management drugs are prescribed in serious to mild pain conditions such as back pain, neck pain, and pain from cancer. Pain management drugs market is highly lucrative due to low availability of alternative drug therapies for treatment of pain. Drug manufacturers are introducing effective generic version in various dosage forms, which is driving the market growth. Chronic pain is one of the highly prevalent pain disorders, which is primarily treated by these medications. The medical management of pain diseases is patient specific and is highly dependent on individual patients’ symptoms.

Market Dynamics

The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.

Key features of the study:

  • This report provides in-depth analysis of pain management drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pain management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pain management drugs market

Detailed Segmentation:

  • Global Pain Management Drugs Market, by Drug Class:
    • Opioids
    • NSAIDs
    • Anticonvulsants
    • Antidepressants
    • Others
  • Global Pain Management Drugs Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pain Management Drugs Market, by Region:
    • North America
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Opioids
        • NSAIDs
        • Anticonvulsants
        • Antidepressants
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Sanofi S.A.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Abbott Laboratories
    • Purdue Pharma L.P.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Hoffmann La Roche Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • PEST Analysis
    • PORTER’s Analysis
    • Regulatory Scenario
  4. Global Pain Management Drugs Market, By Drug Class, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Opioids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • NSAIDs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Anticonvulsants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Muscle Relaxants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  5. Global Pain Management Drugs Market, By Distribution Channel, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2016–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  6. Global Pain Management Drugs Market, By Regions, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eily, Lilly, and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Purdue Pharma L.P.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 55 figures on "Pain Management Drugs Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.